-
11.发明公开VACCINATION AND METHODS AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS 失效疫苗接种引起的特异性T细胞群所产生OUT致病性反应疾病治疗中。
公开(公告)号：EP0623025A1
公开(公告)日：1994-11-09
申请号：EP93902714.0
申请日：1992-12-21
CPC分类号： C07K14/7051 , A61K39/00 , A61K48/00 , A61K2039/53
摘要： L'invention concerne des vaccins ainsi qu'un moyen de vaccination d'un vertébré de manière à prévenir ou à réguler des pathologies induites par des lymphocytes T spécifiques, y compris des maladies auto-immunes ainsi que la réplication non régulée de lymphocytes T. Le vaccin se compose d'un récepteur de lymphocytes T (TCR) ou d'un fragment de celui correspondant à un TCR présent à la surface de lymphocytes induisant la pathologie. Le fragment du vaccin peut être un peptide correspondant à des séquences de TCR caractéristique des lymphocytes T induisant ladite pathologie. Ledit peptide peut se fixer à des antigènes classiques dont la transformation en complexe permet d'obtenir des cellules présentant des antigènes de complexe majeur d'histocompatibilité ou des superantigènes. L'invention concerne également des moyens de détermination des séquences d'acides aminés appropriés destinés à ces vaccins. Le vaccin est administré aux vertébrés d'une manière induisant une réponse immunitaire dirigée contre le TCR de lymphocytes T induisant la pathologie. Cette réponse immunitaire réduit ou supprime les lymphocytes T pathogènes, stoppant ainsi la pathogénèse de la maladie. L'invention concerne également des régions variables à chaînes beta spécifiques des récepteurs de lymphocytes T, appelés Vbeta3, Vbeta4, Vbeta12, Vbeta14 et Vbeta17, lesquels sont associés à la pathogénèse de maladies auto-immunes, telle que la polyarthrite rhumatoïde et la sclérose en plaques. En outre, l'invention concerne des procédés d'administration d'ADN ou d'ARN codant les polypeptides utiles en tant que vaccins de l'invention, dans les cellules tissulaires d'un individu.
-
12.发明公开VACCINATION AND METHODS AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS 失效接种并抵靠特异性T细胞的病理反应的疾病的方法推导。
公开(公告)号：EP0463101A1
公开(公告)日：1992-01-02
申请号：EP90905821.0
申请日：1990-03-21
CPC分类号： C07K14/7051 , A61K39/00 , A61K2039/53 , G01N2800/102
摘要： La présente invention concerne des vaccins et des moyens de vaccination d'un mammifère de manière à empêcher ou contrôler des pathologies induites par des cellules T spécifiques ou pour traiter la réplication non régulée de cellules T. Le vaccin se compose d'un récepteur de cellules T (TCR) ou d'un fragment de celui-ci correspondant à un TCR présent à la surface des cellules T induisant la pathologie. Des moyens de détermination de séquences d'acides aminés appropriés pour de tels vaccins sont également prévus. Le vaccin est administré au mammifère pour qu'il induise une réponse immune dirigée contre le TCR des cellules T induisant la pathologie. Cette réponse immune réduit ou élimine les cellules T pathogéniques, stoppant ainsi la pathogénèse de la maladie. L'invention concerne en outre une région variable à chaîne beta spécifique du récepteur de cellules T, désignée Vbeta17, qui est centrale à la pathogénèse du rhumatisme articulaire (RA). Sont également prévus des moyens de détection, de prévention et de traitement du rhumatisme articulaire.
-
13.发明授权VACCINATION AND METHODS AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS 失效疫苗接种和方法具体对阵T细胞的病理反应疾病衍生
公开(公告)号：EP0463101B2
公开(公告)日：2003-03-19
申请号：EP90905821.6
申请日：1990-03-21
IPC分类号： C07K7/06 , A61K38/03 , G01N33/564 , G01N33/68
CPC分类号： C07K14/7051 , A61K39/00 , A61K2039/53 , G01N2800/102
摘要： The present invention provides vaccines and a means of vaccinating a mammal so as to prevent or control specific T cell mediated pathologies or to treat the unregulated replication of T cells. The vaccine is composed of a T cell receptor (TCR) or a fragment thereof corresponding to a TCR present on the surface of T cells mediating the pathology. The vaccine fragment can be a peptide corresponding to sequences of TCRs characteristic of the T cells mediating said pathology. Means of determining appropriate amino acid sequences for such vaccines are also provided. The vaccine is administered to the mammal in a manner that induces an immune response directed against the TCR of T cells mediating the pathology. This immune response down regulates or deletes the pathogenic T cells, thus ablating the disease pathogenesis. The invention additionally provides a specific beta -chain variable region of the T cell receptor, designated V beta 17, which is central to the pathogenesis of rheumatoid arthritis (RA). Also provided are means to detect, prevent and treat RA.
-
14.发明公开USE OF VIRAL CIS-ACTING POST-TRANSCRIPTIONAL REGULATORY SEQUENCES TO INCREASE EXPRESSION OF INTRONLESS GENES CONTAINING NEAR-CONSENSUS SPLICE SITES 失效病毒顺式作用转录调控序列的后期使用基因的有很多INTRO近共识餐饮区域表达对增强
公开(公告)号：EP0888451A1
公开(公告)日：1999-01-07
申请号：EP97908930.0
申请日：1997-03-10
CPC分类号： C12N9/644 , C07K14/755 , C12N15/85 , C12N2800/108 , C12N2830/42 , C12N2830/48 , C12N2840/44 , C12Y304/21022
摘要： Expression vectors are disclosed comprising intronless genes containing one or more near consensus splice sequences and one or more copies of a viral cis-acting post-transcriptional regulatory element which is transcribed along with the gene and causes export of the gene transcript from the nucleus into the cytoplasm of the cell. In a preferred embodiment, the vectors are targeted for delivery to specific cells in the form of a molecular complex made up of the plasmid releasably linked to a nucleic acid binding agent and a ligand which binds to a component on the surface of a cell. Use of viral cis-acting post-transcriptional regulatory elements as disclosed can increase expression of intronless genes with near-consensus splice sites.
-
15.发明公开Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations 失效和针对来自病理反应衍生的疾病的接种程序引起的特异性T细胞群
公开(公告)号：EP0722738A2
公开(公告)日：1996-07-24
申请号：EP95250317.5
申请日：1992-01-21
IPC分类号： A61K39/00 , A61K39/395 , A61K47/48 , A61K48/00 , G01N33/569
CPC分类号： C07K16/2809 , A61K39/00 , A61K48/00 , A61K2039/53 , C07K14/7051 , C07K16/4258
摘要： The present invention provides vaccines and a means of vaccinating a vertebrate so as to prevent or control specific T cell mediated pathologies, including autoimmune diseases and the unregulated replication of T cells. The vaccine is composed of a T cell receptor (TCR) or a fragment thereof corresponding to a TCR present on the surface of T cells mediating the pathology. The vaccine fragment can be a peptide corresponding to sequences of TCRs characteristic of the T cells mediating said pathology. Such a peptide can bind to conventional antigens complexed to MHC antigen presenting cells or to superantigens. Means of determining appropriate amino acid sequences for such vaccines are also provided. The vaccine is administered to the vertebrate in a manner that induces an immune response directed against the TCR of T cells mediating the pathology. This immune response down regulates or deletes the pathogenic T cells, thus ablating the disease pathogenesis. The invention additionally provides specific β-chain variable regions of T cell receptors, designated Vβ3, Vβ4, Vβ14 and Vβ17, which are associated with the pathogenesis of autoimmune diseases, such as rheumatoid arthritis (RA) and multiple sclerosis (MS). Also provided are means to detect, prevent and treat RA and MS. Methods of administering DNA or RNA encoding the polypeptides useful as vaccines of the present invention into the tissue cells of an individual is also provided.
摘要翻译： 本发明提供了疫苗和疫苗接种脊椎动物，以便防止或控制特定的T细胞介导的病状，包括自身免疫疾病和T细胞的未调节的复制的手段。 该疫苗是由T细胞受体（TCR）或它们对应于TCR本的T细胞介导的病理学的表面上的片段。 疫苗片段可以是对应于T细胞介导所述病理的特征的TCR的序列的肽。 这样的肽可以结合复合的MHC抗原呈递细胞上的抗原的常规或超抗原。 因此，提供为寻求疫苗确定性采矿适当的氨基酸序列的装置。 的疫苗施用于脊椎动物的方式做了诱导定向抗T的TCR的细胞介导的病理学免疫应答。 下调这种免疫应答或删除该致病性T细胞，从而消融所述疾病的发病机理。 本发明另外提供具体的β - 链式T细胞受体的可变区，被指定为V的β3，V的β4，V的β14和V 17的β，这是与自体免疫疾病，：如类风湿性关节炎（RA）的发病机制相关联，并且 多发性硬化（MS）。 因此，提供工具，以检测，预防和治疗RA和MS。 管理的DNA或RNA编码多肽的方法中有用的，作为本发明到个体的组织细胞的疫苗因此提供。
-
公开(公告)号：EP0602761A1
公开(公告)日：1994-06-22
申请号：EP93250368.3
申请日：1988-06-09
发明人： Salk, Jonas , Carlo, Dennis J.
CPC分类号： C07K14/005 , A61M1/3687 , C12N2740/16122
摘要： The present invention provides a composition useful for extracorporeal removal of antibodies to gp160/120 from an individual with HIV, comprising a matrix to which are attached ligands reactive with gp160/120 such that antibodies to gp160/120 will bind to said matrix as well as anti-idiotype antibodies reactive with anti-gp160/120 antibodies.
-
17.发明授权VACCINATION AND METHODS AGAINST DISEASES RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL POPULATIONS 失效接种并抵靠特异性T细胞的病理反应的疾病的方法推导。
公开(公告)号：EP0463101B1
公开(公告)日：1994-01-12
申请号：EP90905821.6
申请日：1990-03-21
IPC分类号： C07K7/06 , A61K37/02 , G01N33/564 , G01N33/68
CPC分类号： C07K14/7051 , A61K39/00 , A61K2039/53 , G01N2800/102
摘要： The present invention provides vaccines and a means of vaccinating a mammal so as to prevent or control specific T cell mediated pathologies or to treat the unregulated replication of T cells. The vaccine is composed of a T cell receptor (TCR) or a fragment thereof corresponding to a TCR present on the surface of T cells mediating the pathology. The vaccine fragment can be a peptide corresponding to sequences of TCRs characteristic of the T cells mediating said pathology. Means of determining appropriate amino acid sequences for such vaccines are also provided. The vaccine is administered to the mammal in a manner that induces an immune response directed against the TCR of T cells mediating the pathology. This immune response down regulates or deletes the pathogenic T cells, thus ablating the disease pathogenesis. The invention additionally provides a specific β-chain variable region of the T cell receptor, designated Vβ17, which is central to the pathogenesis of rheumatoid arthritis (RA). Also provided are means to detect, prevent and treat RA.
-
公开(公告)号：EP0521897A1
公开(公告)日：1993-01-13
申请号：EP91905685.0
申请日：1991-03-13
CPC分类号： A61K39/0011 , A61K2039/5154 , C07K16/4266 , C12N5/0639 , C12N2509/00
摘要： Cette invention fournit un procédé pour induire une réponse immunitaire efficace contre les lymphocytes pathogènes, en administrant des cellules dendritiques auparavant pulsées avec la protéine de l'idiotype recherché. Dans une version de l'invention, on présente un procédé concernant l'immunisation active d'un mammifère contre le lymphome. Cette version comprend l'exposition des cellules dendritiques à l'immuniglobuline (Ig) de l'idiotype pour fabriquer des cellules dendritiques pulsées avec l'idiotype et la réinjection de ces même cellules dendritiques pulsées avec l'idiotype dans le mammifère, ce qui induit alors l'immunité contre les cellules du lymphome. Dans une autre version de l'invention, il s'agit d'administrer les deux types de cellules, à savoir les cellules idiotopiques et les cellules dendritiques pulsées.
-
公开(公告)号：EP0751988A1
公开(公告)日：1997-01-08
申请号：EP95914170.0
申请日：1995-03-22
发明人： HRINDA, Michael, E. , PRIOR, Christopher, P. , MITSCHELEN, Jonathan, J. , IRISH, Thomas, W. , WEBER, David, M. , GORE, Richard, S. , HARTER, James, J. , BAY, Pierre, M. , TARR, George, C.
CPC分类号： C12N7/00 , C07K14/005 , C12N2740/16022 , C12N2740/16051 , C12N2740/16122
摘要： This invention is directed to a continuous process for producing viral particles comprising providing in a perfused growth medium a population of viable virally infected non-lytic cells, and removing medium containing said cells at a rate to maintain the steady-state log-phase growth of cells remaining in said perfused growth medium. The invention is also directed to a process for purifying retroviral particles comprising passing a solution comprising the retroviral particles and contaminants through an anion exchange resin, and eluting the retroviral particles from the resin.
摘要翻译： 本发明涉及生产病毒颗粒的连续方法，包括在灌注的生长培养基中提供存活的病毒感染的非裂解细胞群，并以保持稳态对数期生长的速率除去含有所述细胞的培养基 保留在所述灌注生长培养基中的细胞。 本发明还涉及纯化逆转录病毒颗粒的方法，包括使包含逆转录病毒颗粒和污染物的溶液通过阴离子交换树脂，并从树脂上洗脱逆转录病毒颗粒。
-
公开(公告)号：EP0738281A1
公开(公告)日：1996-10-23
申请号：EP95909258.0
申请日：1995-01-13
CPC分类号： A61K39/0008 , A61K38/00 , A61K39/00 , A61K48/00 , A61K2039/53 , C07K14/7051 , C07K16/2809 , C07K16/4258 , G01N33/56972 , G01N2800/285
摘要： This invention relates to methods of preventing or reducing the severity of psoriasis. In one embodiment, the method involves administering to the individual a peptide having substantially the sequence of a non-conserved region sequence of a T cell receptor present on the surface of T cells mediating psoriasis or a fragment thereof, wherein the peptide or fragment is capable of causing an effect on the immune system to regulate the T cells. In particular, the T cell receptor has the Vβ region Vβ3, Vβ13.1 or Vβ17. In another embodiment, the method involves gene therapy. The invention also relates to methods of diagnosing psoriasis by determining the presence of psoriasis predominant T cell receptors.
-
-
-
-
-
-
-
-
-
搜索结果
28 条记录 (耗时 0.017 秒)
